Pharmaceutical

Delix plans further trials with neuroplastogen after positive Phase I data

The company will initiate Phase Ib and Phase II studies in major depression in 2024 and 2025, respectively.

Jul 16, 2024 - 04:00
Delix plans further trials with neuroplastogen after positive Phase I data
The company will initiate Phase Ib and Phase II studies in major depression in 2024 and 2025, respectively.
Read the original article

Tags:

Previous Article

¬AI model harnesses physics to autocorrect remote sensing data

Next Article

AbbVie looks to add an eighth indication for JAK inhibitor Rinvoq

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy

Replimune kickstarts Phase III melanoma trial studying ...

Aug 15, 2024

EC grants marketing authorisation for Sandoz’s biosimilar Hyrimoz

EC grants marketing authorisation for Sandoz’s biosimil...

Apr 3, 2023

Pierre Fabre announces another partnership to expand oncology R&D

Pierre Fabre announces another partnership to expand on...

Sep 25, 2023